EGFR and neoplasm: In conclusion, in the context of the attempts of numerous immunotherapy combinations in patients with EGFR-positive advanced NSCLS resistant to EGFR-TKIs, benmelstobart plus anlotinib therapy, which shows anti-tumor efficacy, low toxicity, and the convenience of oral administration, could potentially fill the gap in the treatment of this population.